TRDA Key Statistics, Chart & Performance
The current stock price of TRDA is 11.07 USD. In the past month the price increased by 5.83%. In the past year, price decreased by -17.63%.
TRDA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to TRDA. When comparing the yearly performance of all stocks, TRDA turns out to be only a medium performer in the overall market: it outperformed 51.93% of all stocks.
TRDA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TRDA. TRDA has a great financial health rating, but its profitability evaluates not so good.
TRDA Financial Highlights
Over the last trailing twelve months TRDA reported a non-GAAP Earnings per Share(EPS) of -2.49. The EPS decreased by -256.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.06% | ||
| ROE | -30.36% | ||
| Debt/Equity | 0 |
TRDA Forecast & Estimates
11 analysts have analysed TRDA and the average price target is 18.36 USD. This implies a price increase of 65.85% is expected in the next year compared to the current price of 11.07.
For the next year, analysts expect an EPS growth of -302.72% and a revenue growth -83.28% for TRDA
TRDA Ownership
TRDA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.21 | 393.136B | ||
| AMGN | AMGEN INC | 16.27 | 196.357B | ||
| GILD | GILEAD SCIENCES INC | 17.47 | 182.665B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.62 | 117.594B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.77 | 79.341B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.11 | 42.669B | ||
| INSM | INSMED INC | N/A | 31.681B | ||
| NTRA | NATERA INC | N/A | 29.21B | ||
| BIIB | BIOGEN INC | 12.57 | 27.736B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.15 | 20.376B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TRDA
Company Profile
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company is headquartered in Boston, Massachusetts and currently employs 183 full-time employees. The company went IPO on 2021-10-29. The company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The firm is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The company is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. The company has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Company Info
ENTRADA THERAPEUTICS INC
One Design Center Place, Suite 17-500
Boston MASSACHUSETTS US
CEO: Dipal Doshi
Employees: 183
Phone: 18573051825
ENTRADA THERAPEUTICS INC / TRDA FAQ
Can you describe the business of ENTRADA THERAPEUTICS INC?
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company is headquartered in Boston, Massachusetts and currently employs 183 full-time employees. The company went IPO on 2021-10-29. The company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The firm is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The company is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. The company has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
What is the current price of TRDA stock?
The current stock price of TRDA is 11.07 USD. The price increased by 2.31% in the last trading session.
Does ENTRADA THERAPEUTICS INC pay dividends?
TRDA does not pay a dividend.
What is the ChartMill technical and fundamental rating of TRDA stock?
TRDA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for TRDA stock?
11 analysts have analysed TRDA and the average price target is 18.36 USD. This implies a price increase of 65.85% is expected in the next year compared to the current price of 11.07.
Can you provide the sector and industry classification for ENTRADA THERAPEUTICS INC?
ENTRADA THERAPEUTICS INC (TRDA) operates in the Health Care sector and the Biotechnology industry.
What is the next earnings date for TRDA stock?
ENTRADA THERAPEUTICS INC (TRDA) will report earnings on 2026-02-25, after the market close.